JP MORGAN/CALL/BOSTON SCIENTIFIC/72/0.1/17.01.25 | Market Closed - Börse Stuttgart 11:43:30 31/05/2024 BST | ||
| 1.09 EUR | -1.80% |
|
| 1 month | +9.00% | ||
| 3 months | +39.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1.09 | -1.80% |
| 30/05/24 | 1.11 | +0.91% |
| 29/05/24 | 1.1 | -5.98% |
| 28/05/24 | 1.17 | +0.86% |
| 27/05/24 | 1.16 | +0.87% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:43 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK0NCD |
| ISIN | DE000JK0NCD9 |
| Date issued | 26/01/2024 |
| Strike | 72 $ |
| Maturity | 17/01/2025 (229 Days) |
| Parity | 10 : 1 |
| Emission price | 0.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.17 € |
|---|---|
| Lowest since issue | 0.47 € |
| Spread | 0.04 € |
| Spread % | 3.48% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
75.57
USD
Average target price
82.06
USD
Spread / Average Target
+8.59%
- Stock Market
- Warrants
- Warrant
